

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5198884

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CHUNRONG MA	12/01/2004
NARESH NAYYAR	12/01/2004
NEBOJSA SLOBODAN STANKOVIC	12/01/2004
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AGOURON PHARMACEUTICALS, INC.
<b>Street Address:</b>	10777 SCIENCE CENTER DRIVE
<b>City:</b>	SAN DIEGO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>Name:</b>	CANCER RESEARCH TECHNOLOGY LIMITED
<b>Street Address:</b>	ANGEL BUILDING, 407 ST. JOHN STREET
<b>City:</b>	LONDON
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	EC1V 4AD
<b>Name:</b>	PFIZER INC.
<b>Street Address:</b>	235 EAST 42ND STREET
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10017
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	11233845
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-937-2300
<b>Email:</b>	jsteinfield@cooley.com
<b>Correspondent Name:</b>	COOLEY LLP
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE NW
<b>PATENT</b>	

<b>Address Line 2:</b>	SUITE 700
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004

<b>ATTORNEY DOCKET NUMBER:</b>	CLOV-002/001US
--------------------------------	----------------

<b>NAME OF SUBMITTER:</b>	HEIDI A. ERLACHER
---------------------------	-------------------

<b>SIGNATURE:</b>	/Heidi A. Erlacher/
-------------------	---------------------

<b>DATE SIGNED:</b>	10/22/2018
---------------------	------------

**Total Attachments: 2**

source=CLOV002001USAssignment#page1.tif

source=CLOV002001USAssignment#page2.tif

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Chunrong Ma of 12130 Salix Court, San Diego, California 92129, United States of America; Nareesh Nayyar of 7405 Park Village Road, San Diego, California 92129, United States of America; and Nebojsa Slobodan Stanković of 8435 Via Mallorca, #89, La Jolla, California 92037, United States of America; hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America and CANCER RESEARCH TECHNOLOGY LTD., having a place of business at Sardinia House, Sardinia Street, London, WC2A 3NL, United Kingdom, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No. PC26169, entitled **METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS**; filed in the United States Patent and Trademark Office on September 22, 2004 and assigned application number 60/612,457; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America and CANCER RESEARCH TECHNOLOGY LTD., having a place of business at Sardinia House, Sardinia Street, London, WC2A 3NL, United Kingdom, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC., and said PFIZER INC., and said CANCER RESEARCH TECHNOLOGY LTD. and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this first day of December 2004,

at San Diego, California, United States of America

  
Chunrong Ma

In the presence of:

Christa M. Compelube  
Christina M. Compelube  
[print name here, sign above]

Signed and witnessed this 1<sup>st</sup> day of December 2004,

at San Diego, California, United States of America

  
Naresh Nayyar

In the presence of:

Christa M. Compelube  
Christina M. Compelube  
[print name here, sign above]

Signed and witnessed this FIRST day of DECEMBER 2004,

at San Diego, California, United States of America

  
Nebojsa Slobodan Stanković

In the presence of:

Christa M. Compelube  
Christina M. Compelube  
[print name here, sign above]